Skip to main content
Premium Trial:

Request an Annual Quote

BioMérieux and NuGen Ink Cross-License Agreement for Amplification Technologies

This article has been updated from a previous version, which incorrectly stated that BioMérieux acquired exclusive rights to NuGen's amplification system. 
 
NEW YORK (GenomeWeb News) - BioMérieux and NuGen Technologies have signed a cross-license and supply agreement to share amplification technologies for expression analysis, the companies said today.
 
The agreement gives BioMérieux non-exclusive rights to NuGen’s WT-Ovation RNA amplification system, and grants NuGen access to BioMérieux’s linear amplification technology.
 
BioMérieux will use NuGen’s technology to develop microarray-based cancer assays, while NuGen gains original equipment manufacturer rights to BioMérieux’s linear amplification technologies for the research market.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.